Evodiamine improves congnitive abilities in SAMP8 and APPswe/PS1ΔE9 transgenic mouse models of Alzheimer's disease

Abstract

Aim:To investigate the effect of evodiamine (a quinolone alkaloid from the fruit of Evodia rutaecarpa) on the progression of Alzheimer's disease in SAMP8 and APP swe /PS1 ΔE9 transgenic mouse models. Methods: The mice at age of 5 months were randomized into the model group, two evodiamine (50 mg·kg -1 ·d -1 and 100 mg·kg -1 ·d -1 ) groups and an Aricept (2 mg·kg -1 ·d -1 ) group. The littermates of no-transgenic mice and senescence accelerated mouse/resistance 1 mice (SAMR1) were used as controls. After 4 weeks of treatment, learning abilities and memory were assessed using Morris watermaze test, and glucose uptake by the brain was detected using positron emission tomography/computed tomography (PET/CT). Expression levels of IL-1β, IL-6, and TNF-α in brain tissues were detected using ELISA. Expression of COX-2 protein was determined using Western blot. Results: In Morris water-maze test, evodiamine (100 mg·kg -1 ·d -1 ) significantly alleviated the impairments of learning ability and memory. Evodiamine (100 mg·kg -1 ·d -1 ) also reversed the inhibition of glucose uptake due to development of Alzheimer's disease traits in mice. Furthermore, the dose of evodiamine significantly decreased the expression of IL-1β, IL-6, TNF-α, and COX-2 that were involved in the inflammation due to Alzheimer's disease. Conclusion:The results indicate that evodiamine (100 mg·kg -1 ·d -1 ) improves cognitive abilities in the transgenic models of Alzheimer's disease.

Evodiamine Prevents Isoproterenol-Induced Cardiac Fibrosis by Regulating Endothelial-to-Mesenchymal Transition

“…The animals were allowed free access to a standard commercial diet and tap water. The mice were randomly divided into 4 groups (20 per group) for treatment: control, cardiac fibrosis (ISO), and low-and high-dose evodiamine (50 and 100 mg/kg/day, respectively) [37,38]. For the ISO model, ISO (Sigma-Aldrich Co.) was injected subcutaneously in mice at 10 mg/kg/day for 3 days and 5 mg/kg/day for 11 days.…”

MicroPET imaging and transgenic models: a blueprint for Alzheimer's disease clinical research

“…Indeed, patterns of temporarily altered glucose metabolism have already been identified in patients with mild cognitive impairment (MCI) and AD [103]. In APP/PS1 strains, such as APP751sl/PS1 and APPswe/PS1de9 mice, PET [ 18 F]FDG shows brain hypometabolism at the beginning of the plaque formation phase, which occurs at 3 and 6 months, respectively, for these two models [104,105]. Hypometabolism may be associated with the neurodegeneration present in these models.…”

The effect of PN-1, a Traditional Chinese Prescription, on the Learning and Memory in a Transgenic Mouse Model of Alzheimer’s Disease

“…These mice show learning and memory deficits and increased senile plaques in behavioral and neuropathological analyses [16, 17]. The use of animals was in compliance with the National Institutes of Health Guide for Care and Use of Laboratory Animals.…”